Active	Status	Sponsor type	Region	Phase	Filter
9 Active 0 Inactive 9 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

9 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Truong, Daniel
NCT05357989 / 2022-001542-38: A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD	Completed	3	523	Europe, US	buntanetap/posiphen, Posiphen Tartrate, ANVS401, Placebo	Annovis Bio Inc., TFS Trial Form Support	Parkinson's Disease, Idiopathic	12/23	12/23
TEMPO-3, NCT04542499 / 2019-002951-40: Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations	Completed	3	507	Europe, Canada, US, RoW	Tavapadon, PF-06649751, CVL-751, Placebo	AbbVie	Parkinson Disease	01/24	02/24
TEMPO-1, NCT04201093 / 2019-002949-38: Fixed-Dose Trial in Early Parkinson's Disease (PD)	Completed	3	522	Europe, Canada, US, RoW	Tavapadon, PF-06649751, CVL-751, Placebo	Cerevel Therapeutics, LLC	Parkinson Disease	06/24	06/24
ORION, NCT06122662: AMX0035 and Progressive Supranuclear Palsy	Active, not recruiting	2/3	110	Europe, US	AMX0035, Placebo	Amylyx Pharmaceuticals Inc.	Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism	04/26	11/29
NCT05979415: Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes	Terminated	2	8	US	Apomorphine Cartridge, placebo	Alexza Pharmaceuticals, Inc., Peachtree BioResearch Solutions, DSG, ISS, Inc.	Parkinson Disease	02/24	02/24
SHIMMER, NCT05225415: Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects with Mild to Moderate Dementia with Lewy Bodies	Completed	2	130	US	CT1812	Cognition Therapeutics, National Institute on Aging (NIA)	Dementia with Lewy Bodies	11/24	11/24
MTR-601-201, NCT06830642: Study of the Oral Treatment MTR-601 in Cervical Dystonia	Recruiting	2	80	US	MTR-601, Placebo	Motric Bio	Cervical Dystonia	07/26	08/26
NCT05923866: A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy	Active, not recruiting	2	92	Japan, US	ONO-2808, Placebo	Ono Pharmaceutical Co. Ltd	Multiple System Atrophy (MSA)	08/25	08/25
Washington, Kadijah
SIGNAL-AA, NCT06018428: A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata	Recruiting	2	75	US	bempikibart (ADX-914)	Q32 Bio Inc., Innovaderm Research Inc.	Alopecia Areata	06/26	09/26

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Truong, Daniel
NCT05357989 / 2022-001542-38: A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD	Completed	3	523	Europe, US	buntanetap/posiphen, Posiphen Tartrate, ANVS401, Placebo	Annovis Bio Inc., TFS Trial Form Support	Parkinson's Disease, Idiopathic	12/23	12/23
TEMPO-3, NCT04542499 / 2019-002951-40: Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations	Completed	3	507	Europe, Canada, US, RoW	Tavapadon, PF-06649751, CVL-751, Placebo	AbbVie	Parkinson Disease	01/24	02/24
TEMPO-1, NCT04201093 / 2019-002949-38: Fixed-Dose Trial in Early Parkinson's Disease (PD)	Completed	3	522	Europe, Canada, US, RoW	Tavapadon, PF-06649751, CVL-751, Placebo	Cerevel Therapeutics, LLC	Parkinson Disease	06/24	06/24
ORION, NCT06122662: AMX0035 and Progressive Supranuclear Palsy	Active, not recruiting	2/3	110	Europe, US	AMX0035, Placebo	Amylyx Pharmaceuticals Inc.	Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism	04/26	11/29
NCT05979415: Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes	Terminated	2	8	US	Apomorphine Cartridge, placebo	Alexza Pharmaceuticals, Inc., Peachtree BioResearch Solutions, DSG, ISS, Inc.	Parkinson Disease	02/24	02/24
SHIMMER, NCT05225415: Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects with Mild to Moderate Dementia with Lewy Bodies	Completed	2	130	US	CT1812	Cognition Therapeutics, National Institute on Aging (NIA)	Dementia with Lewy Bodies	11/24	11/24
MTR-601-201, NCT06830642: Study of the Oral Treatment MTR-601 in Cervical Dystonia	Recruiting	2	80	US	MTR-601, Placebo	Motric Bio	Cervical Dystonia	07/26	08/26
NCT05923866: A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy	Active, not recruiting	2	92	Japan, US	ONO-2808, Placebo	Ono Pharmaceutical Co. Ltd	Multiple System Atrophy (MSA)	08/25	08/25
Washington, Kadijah
SIGNAL-AA, NCT06018428: A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata	Recruiting	2	75	US	bempikibart (ADX-914)	Q32 Bio Inc., Innovaderm Research Inc.	Alopecia Areata	06/26	09/26